How should a febrile non‑hemolytic transfusion reaction be managed?

Management of Febrile Non-Hemolytic Transfusion Reaction

Immediately stop the transfusion, maintain IV access, and administer antipyretic medication (acetaminophen) for symptomatic relief while excluding more serious transfusion reactions through clinical assessment and laboratory evaluation. 1

Immediate Actions When FNHTR is Suspected

When a patient develops fever (≥38°C or temperature rise ≥1°C) with or without chills during or within 4 hours of transfusion, take these steps: 2

• Stop the transfusion immediately and keep the IV line open with normal saline 1
• Notify the blood bank and transfusion service immediately 1
• Perform bedside clerical check to verify correct patient and blood product 3
• Assess vital signs and clinical status to exclude hemolytic reactions, septic transfusion reactions, TRALI, or TACO 1

Diagnostic Workup

The clinical burden of FNHTR extends beyond the reaction itself, with substantial downstream diagnostic activity: 3

• Blood cultures are obtained in approximately 79% of cases to exclude bacterial contamination 3
• Chest imaging is performed in about 25% of patients within 48 hours to rule out TRALI or TACO 3
• Send the blood product and post-transfusion blood sample to the blood bank for evaluation 1
• Consider that approximately one-third of FNHTR patients develop significant fevers (≥39°C or rise ≥2°C), warranting more extensive evaluation 3

Symptomatic Treatment

Once more serious reactions are excluded:

• Administer acetaminophen for fever control as the primary symptomatic treatment 2, 4
• Provide supportive care including sedation if needed for severe rigors 2
• Monitor the patient until symptoms resolve 1
• Note that 15% of outpatients with FNHTR require hospital admission specifically to exclude other causes of fever 3

Critical Pitfall: Prophylactic Premedication

The routine prophylactic use of antipyretics before transfusion remains controversial and is not recommended as standard practice. 2, 5

• Studies show that prophylactic acetaminophen or diphenhydramine is prescribed before more than 50% of transfusions in the US, yet these medications have failed to prevent transfusion reactions in studies performed to date 5
• One institution reported only 0.09% FNHTR incidence with 80% of transfusions preceded by antipyretics, but this low rate may reflect leukoreduction rather than premedication efficacy 4
• Routine premedication may mask early signs of more serious reactions and has potential toxicity in ill patients 5
• Reserve premedication only for patients with documented history of recurrent FNHTRs 2, 5

Prevention Strategies

The most effective prevention approach:

• Prestorage leukoreduction significantly reduces FNHTR incidence from 2.15% with poststorage leukoreduction to 1.1% with prestorage leukoreduction 6
• The overall FNHTR rate with prestorage leukoreduced components is approximately 0.17% for RBCs and 0.25% for platelets 3
• Leukocyte removal addresses both immune mechanisms (anti-HLA antibodies) and non-immune mechanisms (cytokines released during storage) 2

Risk Factors to Consider

Identify high-risk patients who may warrant closer monitoring:

• Women with reproductive history and patients with multiple prior transfusions are at higher risk 2
• Primary hematologic disease, malignancy, and transfusion of >6 units of leukocyte-depleted packed RBCs are independent risk factors 2
• These patients may benefit from slower transfusion rates and enhanced monitoring 2

Documentation and Reporting

• Report all FNHTRs to the institutional hemovigilance system 1
• Document the reaction details, management, and patient outcome 1
• Any symptom occurring within 24 hours of transfusion should be considered a transfusion reaction and reported 1